GLP-1 Peptide Comparison
Compare efficacy, mechanisms, and approval status across all GLP-1 and incretin-based therapies
Peptide | Mechanism | Weight Loss | Status | Dosing | Key Advantage |
|---|---|---|---|---|---|
| CagriSemaREDEFINE 2 (2024) | Amylin/GLP-1 | 25.3% | Phase 3 | Weekly Max: 2.4mg/2.4mg | Highest efficacy, dual pathways |
| RetatrutideTRIUMPH-2 (2023) | Triple | 24.2% | Phase 3 | Weekly Max: 12mg | Triple agonist, highest weight loss |
| TirzepatideSURMOUNT-1 (2022) | GLP-1/GIP | 20.9% | FDA Approved | Weekly Max: 15mg | Dual mechanism, superior weight loss |
| SurvodutideACHIEVE (2024) | GLP-1/Glucagon | 19% | Phase 3 | Weekly Max: 4.8mg | MASH benefits, metabolic effects |
| MazdutideGLORY-1 (2023) | GLP-1/Glucagon | 18.6% | Phase 3 | Weekly Max: 9mg | Glucagon boost, liver benefits |
| PemvidutideMOMENTUM (2023) | GLP-1/Glucagon | 15.6% | Phase 2 | Weekly Max: 2.4mg | MASH focus, liver health |
| SemaglutideSTEP 1 (2021) | GLP-1 | 15.2% | FDA Approved | Weekly Max: 2.4mg | Gold standard, extensive safety data |
| OrforglipronATTAIN (2023) | GLP-1 | 14.7% | Phase 3 | Daily Max: 45mg | Oral, no fasting required |
| CagrilintideREDEFINE 1 (2023) | Amylin | 10.8% | Phase 3 | Weekly Max: 2.4mg | Novel amylin pathway, complements GLP-1 |
weight loss
Highest efficacy, dual pathways
weight loss
Triple agonist, highest weight loss
weight loss
Dual mechanism, superior weight loss
weight loss
MASH benefits, metabolic effects
weight loss
Glucagon boost, liver benefits
weight loss
MASH focus, liver health
weight loss
Gold standard, extensive safety data
weight loss
Novel amylin pathway, complements GLP-1
Weight loss percentages from clinical trials. Individual results vary. Discuss options with a healthcare provider.
FDA Approved Options
Semaglutide and Tirzepatide are currently FDA-approved for weight management with extensive safety data.
Compare Sema vs Tirz →Highest Efficacy
CagriSema and Retatrutide show the highest weight loss in trials (24-25%), though still in Phase 3.
Compare Next-Gen GLP-1s →Understanding the Mechanisms
GLP-1
Glucagon-like peptide-1 reduces appetite and slows gastric emptying. The foundation of this drug class.
GLP-1/GIP
Adding GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and may reduce nausea.
GLP-1/Glucagon
Glucagon component increases energy expenditure and may improve liver fat metabolism.
Triple Agonist
Combines GLP-1, GIP, and Glucagon for maximum metabolic impact across multiple pathways.
Amylin
Amylin analogs work on different satiety pathways, complementing GLP-1 effects.
Combination
CagriSema combines amylin (Cagrilintide) with GLP-1 (Semaglutide) for dual-pathway action.